CD4+ T cell subsets in adult allergic rhinitis patients attending Hospital Universiti Sains Malaysia by Sani, Mastura Md
CD4+ T CELL SUBSETS IN ADULT ALLERGIC 
RHINITIS PATIENTS ATTENDING HOSPITAL 
UNIVERSITI SAINS MALAYSIA 
 
 
 
 
MASTURA BINTI MD SANI 
 
 
 
 
 
UNIVERSITI SAINS MALAYSIA 
2018 
CD4+ T CELL SUBSETS IN ADULT ALLERGIC 
RHINITIS PATIENTS ATTENDING HOSPITAL 
UNIVERSITI SAINS MALAYSIA 
 
 
 
by 
 
 
 
MASTURA BINTI MD SANI 
 
 
Thesis submitted in fulfillment of the requirements 
for the Degree of  
Master of Science 
 
 
September 2018 
  
ii 
 
ACKNOWLEDGEMENTS 
 
In the name of Allah, the Most Generous and the Most Merciful. All praise 
for Him for His guidance and blessing for me throughout this study. 
First and foremost, I would like to express my gratitude to my supervisor, Dr. 
Tina Tan Hern Tze for giving me the opportunity to conduct this project. Her 
guidance and warm support have helped me a lot to complete this study and thank 
you for always believing in my potential. Her supervision has made me understand 
about holistic education and her passion in allergy and allergology is such an 
inspiration and that drives me to become a better allergy researcher in the future. 
I would also like to express my gratitude to my co-supervisors, Prof. Dr. 
Baharudin Abdullah and Dr. Noor Suryani Mohd Ashari for their assistance and kind 
supervision. My special thanks to Dr. Rohimah Mohamud and Dr Wong Kah Keng 
for their expertise in flow cytometry and Assoc. Prof. Dr. Kamarul Imran Musa for 
his expertise in biostatistics. Thank you to all for the valuable advice and support. 
My sincere appreciation to patients and controls for their participation; the 
physicians and nurses from ORL-HNS clinic in Hospital USM for their help in 
recruitment and blood sample collection; Mr. Jamaruddin Mat Asan and Ms. Fazilah 
Ibrahim from Department of Immunology USM for their technical assistance in 
handling flow cytometer and ImmunoCAP Phadia 100.  
My warm and everlasting gratitude is dedicated to my parents and family 
members for their prayers, sacrifice and continuous support. My special thanks to my 
immunology research laboratory members; Sya, Anes, Siti, Fairus, Mai and Dr. Suet 
Kee for the friendship, help and support throughout this study.  
  
iii 
 
Last but not least, my sincere appreciation goes to USM Fellowship Scheme 
for providing financial support for my postgraduate study and USM Short Term 
Grant (304/PPSP/61313076) for providing financial support for this study. Finally, 
thank you to all who have contributed directly or indirectly in this study.  
May Allah bless all of you. 
 
Mastura Md Sani 
P-UM0007/15(R) 
  
iv 
 
TABLE OF CONTENTS 
 
ACKNOWLEDGEMENTS ......................................................................................... ii 
LIST OF TABLES ...................................................................................................... ix 
LIST OF FIGURES..................................................................................................... xi 
LIST OF ABBREVIATIONS ................................................................................... xiii 
LIST OF APPENDICES .......................................................................................... xvii 
ABSTRAK .............................................................................................................. xviii 
ABSTRACT ............................................................................................................... xx 
 
CHAPTER 1: INTRODUCTION ................................................................................ 1 
1.1 Background of study ........................................................................................... 1 
1.2 Problem statement .............................................................................................. 4 
1.3 Theoretical framework........................................................................................ 4 
1.4 Research questions ............................................................................................. 6 
1.5 Purpose of study ................................................................................................. 6 
1.6 Rationale of study population ............................................................................. 7 
1.7 Objectives ........................................................................................................... 8 
1.7.1 General objective ................................................................................... 8 
1.7.2 Specific objectives ................................................................................. 8 
1.8 Hypothesis .......................................................................................................... 9 
 
 
CHAPTER 2: LITERATURE REVIEW ................................................................... 10 
2.1 Allergy .............................................................................................................. 10 
  
v 
 
2.2 Allergic rhinitis (AR) ........................................................................................ 12 
2.2.1 Prevalence of AR ................................................................................. 12 
2.2.2 Aetiology of AR ................................................................................... 15 
2.2.3 Predisposing factors of AR .................................................................. 16 
2.2.4 Diagnosis of AR ................................................................................... 19 
2.2.5 Treatment of AR .................................................................................. 22 
2.3 Immunopathogenesis of AR ............................................................................. 25 
2.3.1 Early and late phase allergic response ................................................. 25 
2.3.2 Local and systemic inflammation ........................................................ 29 
2.4 Immune cells in allergic inflammation ............................................................. 30 
2.4.1 Mast cells ............................................................................................. 30 
2.4.2 Basophils .............................................................................................. 31 
2.4.3 Eosinophils ........................................................................................... 31 
2.4.4 Macrophages and dendritic cells .......................................................... 32 
2.4.5 TH2 cells & TH2 cytokines ................................................................... 33 
2.4.6 TH1 cells ............................................................................................... 36 
2.5 The role of CD4+ memory T cells in allergy .................................................... 38 
2.6 CD4+ memory T cell subsets and their markers ............................................... 39 
2.6.1 Markers ................................................................................................ 39 
2.6.2 Naïve T cells ........................................................................................ 40 
2.6.3 Central memory T cells ........................................................................ 41 
2.6.4 Effector memory T cells....................................................................... 42 
2.6.5 Terminally differentiated effector memory T cells .............................. 43 
CHAPTER 3: METHODOLOGY ............................................................................. 44 
3.1 Study location ................................................................................................... 44 
  
vi 
 
3.2 Study duration ................................................................................................... 44 
3.3 Study design ..................................................................................................... 44 
3.4 Sampling ........................................................................................................... 45 
3.4.1 Study population .................................................................................. 45 
3.4.2 Sampling population ............................................................................ 45 
3.4.3 Sampling frame .................................................................................... 46 
3.4.4 Sampling unit ....................................................................................... 47 
3.4.5 Sampling method ................................................................................. 47 
3.4.6 Sampling size ....................................................................................... 48 
3.5 Data and sample collection ............................................................................... 49 
3.6 Instrument ......................................................................................................... 52 
3.6.1 Consumables ........................................................................................ 52 
3.6.2 Chemicals and reagents ........................................................................ 52 
3.6.3 Laboratory equipments......................................................................... 53 
3.6.4 Fluorochrome-conjugated antibodies ................................................... 54 
3.7 Blood sample processing .................................................................................. 54 
3.7.1 Blood collection ................................................................................... 54 
3.7.2 Leukocytes count measurement ........................................................... 55 
3.7.3 Plasma total and specific IgE measurement ......................................... 56 
3.7.4 PBMCs isolation by density gradient centrifugation ........................... 59 
3.7.5 CD4+ T cell subsets determination ....................................................... 62 
3.8 Variables ........................................................................................................... 64 
3.9 Statistical analysis ............................................................................................. 66 
3.10 Definition of terms ............................................................................................ 67 
3.11 Study flowchart ................................................................................................. 69 
  
vii 
 
 
CHAPTER 4: RESULTS ........................................................................................... 70 
4.1 Demographic and clinical characteristics of non-allergic controls................... 70 
and AR patients 
4.2 Total IgE and specific IgE to common allergens.............................................. 73 
4.2.1 Levels of total IgE and specific IgE to common allergens .................. 73 
4.2.2 AR patients sensitized to common allergens ....................................... 74 
4.3 Assessment of symptom severity and quality of life scores in AR patients ..... 77 
4.4 Absolute count of leukocyte subsets ................................................................ 80 
4.4.1 Absolute count of leukocyte subsets in non IgE-mediated .................. 80 
AR patients 
4.4.2 Absolute count of leukocyte subsets of IgE-mediated ......................... 82 
AR patients 
4.5 Percentage and absolute count of CD4+ T cell subsets..................................... 83 
4.5.1 Percentage and absolute count of CD4+ T cell subsets in .................... 84 
non IgE-mediated AR patients 
4.5.2 Percentage and absolute count of CD4+ T cell subsets in .................... 89 
  IgE-mediated AR patients 
4.5.3 Symptoms classification of IgE-mediated AR patients ....................... 92 
4.6 Results summary ............................................................................................... 95 
 
CHAPTER 5: DISCUSSION ..................................................................................... 96 
5.1 Demographic and clinical data ......................................................................... 96 
5.2 IgE and sensitization ....................................................................................... 101 
5.3 Symptom severity scores and quality of life .................................................. 104 
  
viii 
 
5.4 Leukocyte count ............................................................................................. 108 
5.5 CD4+ memory T cell subsets .......................................................................... 109 
5.6 Limitations ...................................................................................................... 115 
 
CHAPTER 6: CONCLUSION ................................................................................. 118 
REFERENCES ......................................................................................................... 120 
APPENDICES 
LIST OF PUBLICATION AND CONFERENCE ATTENDED 
 
  
ix 
 
LIST OF TABLES 
  Page 
Table 2.1 Prevalence of allergic rhinitis in South East Asia 
Countries 
14 
Table 3.1 Inclusion and exclusion criteria of cases and controls 46 
Table 3.2 Severity of AR from ARIA guidelines 47 
Table 3.3 Indicator of the 7-point visual analog scale to assess the 
AR nasal and non-nasal symptom severity scores 
50 
Table 3.4 Indicator of the 7-point visual analog scale to assess the 
effect of (i) nasal and non-nasal symptoms severity; and 
(ii) rhinitis severity in the quality of life scores of AR 
patients 
51 
Table 3.5 Consummables used in this study 52 
Table 3.6 Chemicals and reagents used in this study 52 
Table 3.7 Laboratory equipments used in this study 53 
Table 3.8 Fluorochrome-conjugated antibodies used in this study 
for flow cytometry 
54 
Table 3.9 SYSMEX XS-800i automated hematology analyzer 
analysis parameters and results output 
56 
Table 3.10 Dependent variables 65 
Table 3.11 Independent variables 65 
Table 4.1 Demographic and clinical characteristics of non-allergic 
controls and allergic rhinitis patients 
72 
Table 4.2 Levels of total IgE and specific IgE to common 
allergens of non-allergic controls and allergic rhinitis 
74 
  
x 
 
patients 
Table 4.3 Rate of sensitization to common allergens in allergic 
rhinitis patients 
76 
Table 4.4 Allergens reported by allergic rhinitis patients based on 
their history of allergy 
77 
Table 4.5 Nasal and non-nasal symptom severity scores of mild 
allergic rhinitis (AR) patients and moderate-severe AR 
patients 
79 
Table 4.6 The effect of (i) nasal and non-nasal symptom severity; 
and (ii) rhinitis severity in the quality of life scores of 
mild allergic rhinitis (AR) patients and moderate-severe 
AR patients 
80 
Table 4.7 Absolute count of leukocyte subsets in non-allergic 
controls and non IgE-mediated allergic rhinitis patients 
81 
Table 4.8 Absolute count of leukocyte subsets in non IgE-
mediated mild allergic rhinitis (AR) patients and non 
IgE-mediated moderate-severe AR patients 
81 
Table 4.9 Absolute count of leukocyte subsets in non-allergic 
controls and IgE-mediated allergic rhinitis patients 
82 
Table 4.10 Absolute count of leukocyte subsets in IgE-mediated 
mild allergic rhinitis (AR) patients and IgE-mediated 
moderate-severe AR patients 
83 
Table 4.11 Summary of results 95 
  
xi 
 
LIST OF FIGURES 
  Page 
Figure 1.1 Theoretical framework of determinants of perennial 
allergic rhinitis 
5 
Figure 2.1 The incidence of atopic march 11 
Figure 2.2 Prevalence of allergic rhinitis in different regions of 
the world 
13 
Figure 2.3 Summary of allergic rhinitis severity and classification 
of symptoms based on Allergic Rhinitis and its Impact 
on Asthma guidelines 
22 
Figure 2.4 Early and late phase allergic responses 28 
Figure 2.5 CD4+ memory T cell subsets with different migration 
preferences 
40 
Figure 3.1 Peripheral blood mononuclear cells (PBMCs) isolation 
by density gradient centrifugation technique 
60 
Figure 3.2 Hemocytometer 62 
Figure 3.3 Total CD4+ T cells and CD4+ T cell subsets gating 
strategy 
63 
Figure 3.4 Study flowchart 69 
Figure 4.1 Mean percentages of CD4+ T cells between non-
allergic controls and non IgE-mediated AR patients 
85 
Figure 4.2 Mean absolute counts of CD4+ T cells between non-
allergic controls and non IgE-mediated AR patients 
86 
Figure 4.3 Mean percentages of CD4+ T cells between non IgE-
mediated mild AR patients and non IgE-mediated 
87 
  
xii 
 
moderate-severe AR patients 
Figure 4.4 Mean absolute counts of CD4+ T cells between non 
IgE-mediated mild AR patients and non IgE-mediated 
moderate-severe AR patients 
88 
Figure 4.5 Mean percentage and mean absolute count of total 
CD4+ T cells between non-allergic controls and IgE-
mediated AR patients 
89 
Figure 4.6 Mean percentages of CD4+ T cells between non-
allergic controls and IgE-mediated AR patients 
90 
Figure 4.7 Mean absolute counts of CD4+ T cells between non-
allergic controls and IgE-mediated AR patients 
91 
Figure 4.8 Mean percentages of CD4+ T cells between IgE-
mediated mild AR patients and IgE-mediated 
moderate-severe AR patients 
93 
Figure 4.9 Mean absolute counts of CD4+ T cells between IgE-
mediated mild AR patients and IgE-mediated 
moderate-severe AR patients 
94 
 
  
xiii 
 
LIST OF ABBREVIATIONS 
 
AC allergic conjunctivitis 
AD atopic dermatitis 
AIDS acquired immune deficiency syndrome 
ANOVA analysis of variance 
AR allergic rhinitis 
ARIA Allergic Rhinitis and its Impact on Asthma 
ATRA all-trans retinoic acid 
BMI body mass index 
CCL chemokine (C-C motif) ligand 
CCR chemokine (C-C motif) receptor 
CD34+ hematopoietic progenitor cells   
CD4+ helper T cells 
CD62L L-selectin 
CLA cutaneous leucocyte-associated antigen 
Der f Dermatophagoides farinae 
Der p Dermatophagoides pteronyssinus 
DNA deoxyribonucleic acid 
ECP eosinophil cationic protein 
EDN eosinophil-derived neurotoxin 
EDTA ethylenediaminetetraacetic acid 
ELISA enzyme-linked immunosorbent assay 
FACS fluorescence-activated cell sorting 
FcεRI Fc epsilon RI 
  
xiv 
 
FEIA fluoroenzymeimmunoassay 
FinEsS Finland, Estonia and Sweden 
FSC forward-scattered 
GATA3 GA-TA binding protein 3 
GM-CSF granulocyte macrophage colony-stimulating factor 
HDMs house dust mites 
HIV human immunodeficiency virus 
HUSM Hospital Universiti Sains Malaysia 
ICAM intercellular adhesion molecule 
IDM Instrument Data Manager 
IFN-γ interferon gamma 
IgE immunoglobulin E 
IgG immunoglobulin G 
IL interleukin 
IQR interquartile range 
IRF4 interferon regulatory factor 4 
ISAAC International Study of Asthma and Allergies in Childhood 
ISAC immuno-solid phase allergen chip 
kg kilogram 
KLRG1 killer cell lectin like receptor G1 
LFA-1 lymphocyte function-associated antigen 1 
LTC4 leukotriene C4 
m meter 
MBP major basic protein 
MCP-4 monocyte chemotactic protein-4 
  
xv 
 
MIP macrophage inflammatory proteins 
miR-135a microRNA-135a 
ml millilitre 
mRNA messenger ribonucleic acid 
n number 
NA not applicable 
OLIN Obstructive Lung Disease in Northern Sweden 
ORL-HNS Otorhinolaryngology-Head and Neck Surgery 
PBMCs peripheral blood mononuclear cells 
PBS phosphate buffered saline 
PS Power and Sample Size Calculation 
RANTES regulated upon activation normal T cell expressed and 
presumably secreted 
SCF stem cell factor 
SCIT subcutaneous immunotherapy 
SD standard deviation 
SIT specific immunotherapy 
SLIT sublingual immunotherapy 
SPSS Statistical Package for the Social Sciences 
SSC side-scattered 
TARC thymus and activation-regulated chemokine 
TCM central memory T cells 
TCR T cell receptor 
TEM effector memory T cells 
TEMRA terminally differentiated effector memory T cells 
  
xvi 
 
TGF-β transforming growth factor beta 
TH CD4
+ T lymphocytes 
Thy lymphatic endothelial cells 
TN naïve T cells 
TNF-α tumor necrosis factor alpha 
TSA Trichostatin A 
TSLP thymic stromal lymphopoietin 
VAS visual analog scale 
VCAM-1 vascular cell adhesion molecule 1 
VLA very late antigen 
% percentage 
oC degree Celsius 
µl microlitre 
α alpha 
β beta 
γ gamma 
 
  
xvii 
 
LIST OF APPENDICES 
 
Appendix A Consent form 
Appendix B Pro Forma 
Appendix C Ethical approval 
 
  
xviii 
 
SUBSET SEL CD4+ T BAGI PESAKIT ALLERGIC RHINITIS DEWASA DI 
HOSPITAL UNIVERSITI SAINS MALAYSIA 
 
ABSTRAK 
 
Sel T memori mengeluarkan fungsi effector atau menghasilkan sel effector 
sebagai tindak balas terhadap antigen. Peratusan subset sel CD4+ T terutamanya sel-
sel memori dalam pesakit allergic rhinitis (AR; alahan radang hidung) yang sensitif 
kepada alergen umum termasuklah habuk rumah dan makanan laut tidak dikaji 
secara meluas. Kajian ini bertujuan untuk membandingkan purata peratusan dan 
jumlah mutlak subset sel memori CD4+ T antara: (i) individu sihat dan pesakit AR 
(ii) pesakit AR ringan dan pesakit AR yang sederhana-teruk. Di samping itu, tahap 
sensitif terhadap alergen, skor tahap keterukan simptom, dan purata jumlah mutlak 
subset leukosit juga dianalisa. Lima puluh individu sihat dan 100 pesakit AR yang 
telah didiagnosis oleh doktor pakar telah direkrut dalam kajian ini. Walau 
bagaimanapun, hanya 33 individu sihat dimasukkan ke dalam analisis kerana 
individu yang lain adalah sensitif kepada alergen (Dermatophagoides farinae (Der f), 
ketam dan udang) berdasarkan ujian spesifik IgE yg dilakukan. Analisis berstrata 
dilakukan berdasarkan dua definisi pesakit, iaitu pesakit AR berdasarkan (i) bukan 
pengantaraan IgE; dan (ii) pengantaraan IgE. “Flow cytometry” digunakan untuk 
melihat peratusan sel CD4+ T “naïve” (TN; CD45RA+ CCR7+), “central memory” 
(TCM; CD45RA
- CCR7+), “effector memory” (TEM; CD45RA- CCR7-) dan 
“terminally differentiated effector memory” (TEMRA; CD45RA+ CCR7-) dari dalam 
darah. Jumlah mutlak subset sel CD4+ T diperolehi daripada gabungan dua kaedah 
iaitu “flow cytometry” dan “hematology analyzer”. Didapati bahawa pesakit AR 
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yang sensitif kepada alergen (Dermatophagoides pteronyssinus, Der f, ketam and 
udang) kebanyakannya sensitif kepada habuk rumah berbanding dengan makanan 
laut. Pesakit AR sederhana-teruk mempunyai skor simptom nasal dan bukan nasal 
yang tinggi serta kualiti hidup yang lebih terjejas berbanding dengan pesakit AR 
ringan. Tambahan pula, kiraan eosinofil adalah lebih tinggi pada pesakit AR 
berdasarkan pengantaraan IgE berbanding dengan individu sihat. Tidak terdapat 
perbezaan yang signifikan dalam purata peratusan dan jumlah mutlak sel memori 
CD4+ T antara individu sihat dan pesakit AR berdasarkan pengantaraan IgE. Walau 
bagaimanapun, pengurangan yang ketara dalam purata peratusan (p = 0.0287) dan 
jumlah mutlak (p = 0.0298) sel CD4+ TEMRA telah dilihat pada pesakit AR sederhana-
teruk berdasarkan pengantaraan IgE berbanding dengan pesakit AR ringan 
berdasarkan pengantaraan IgE dan 14/25 (56.0%) pesakit AR sederhana-teruk 
berdasarkan pengantaraan IgE mempunyai simptom yang berterusan. 
Kesimpulannya, purata peratusan dan jumlah mutlak sel CD4+ CD45RA+ CCR7- 
TEMRA dilihat berkurang pada pesakit AR sederhana-teruk berdasarkan pengantaraan 
IgE berbanding dengan pesakit AR ringan berdasarkan pengantaraan IgE dalam 
populasi pesakit AR yang kebanyakannya sensitif kepada habuk rumah. 
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CD4+ T CELL SUBSETS IN ADULT ALLERGIC RHINITIS PATIENTS 
ATTENDING HOSPITAL UNIVERSITI SAINS MALAYSIA 
 
ABSTRACT 
 
Memory T cells exert effector function or generate effector cells in response 
to antigen. The proportions of CD4+ T cell subsets especially memory cells in 
allergic rhinitis (AR) patients sensitized to common allergens of house dust mites 
(HDMs) and shellfish have not been extensively studied. This study aimed to 
compare the mean percentages and absolute counts of CD4+ memory T cell subsets 
between: (i) non-allergic controls and AR patients; (ii) mild AR patients and 
moderate-severe AR patients. In addition, sensitization to common allergens, 
symptom severity scores, and mean absolute counts of leukocyte subsets were also 
determined. Fifty non-allergic controls and 100 AR patients diagnosed by physicians 
were recruited in this study. However, only 33 non-allergic controls were included in 
the analyses as others were excluded due to sensitization to the common allergens 
(Dermatophagoides farinae (Der f), crab and shrimp) as measured by plasma 
specific IgE tests. Stratified analyses were done based on two different definitions of 
AR patients , i.e. (i) non IgE-mediated AR patients; and (ii) IgE-mediated AR 
patients. Flow cytometry was used to determine the percentage of CD4+ naïve (TN; 
CD45RA+ CCR7+), central memory (TCM; CD45RA
- CCR7+), effector memory 
(TEM; CD45RA
- CCR7-) and terminally differentiated effector memory (TEMRA; 
CD45RA+ CCR7-) T cells from the peripheral blood. The absolute counts of CD4+ T 
cell subsets were obtained by dual platform methods from flow cytometer and 
hematology analyzer. It was observed that AR patients sensitized to common 
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allergens (Dermatophagoides pteronyssinus, Der f, crab and shrimp) measured were 
predominantly sensitized to HDMs as compared to shellfish allergens. Moderate-
severe AR patients had higher nasal and non-nasal symptom scores and reduced 
quality of life as compared to mild AR patients. Furthermore, the eosinophil count 
was significantly higher in IgE-mediated AR patients as compared to non-allergic 
controls. There were no significant differences in the mean percentages and absolute 
counts of CD4+ T cell subsets between non-allergic controls and IgE-mediated AR 
patients. However, significant reduction in the mean percentage (p = 0.0287) and 
absolute count (p = 0.0298) of CD4+ TEMRA cells were found in IgE-mediated 
moderate-severe AR patients as compared to IgE-mediated mild AR patients and 
14/25 (56.0%) IgE-mediated moderate-severe AR patients had persistent symptoms. 
In conclusion, the mean percentage and absolute count of CD4+ CD45RA+ CCR7- 
TEMRA cells were siginificantly reduced in IgE-mediated moderate-severe AR 
patients as compared to IgE-mediated mild AR patients in our population of AR 
patients predominantly sensitized to HDMs. 
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CHAPTER 1 
 
INTRODUCTION 
 
This chapter provides the overview of this study. The background of study, 
research problems, theoretical framework, research questions, purpose of study, 
rationale of study, objectives and hypothesis of this study are described in detailed in 
this chapter. 
 
1.1 Background of study 
The immune system in human body is essential for a human to stay healthy. It 
protects the human body against microorganisms such as bacteria, viruses and fungi 
by destroying these infectious microorganisms out of the body. The immune system 
is incredibly complex as it is made up of vital network of cells and organs that 
protect the body from infections and other diseases. Allergic disease is one of the 
diseases that results from the immune system’s response to a harmless substance. 
The immune system may over react by producing antibodies towards the harmless 
substance which results in the clinical symptoms of allergic disease.  
The immune system has the ability to immediately and specifically recognize 
an antigen that the body has encountered before. This is known as immunological 
memory where the immune system will immediately initiate an immune response 
after the recognition of previously encountered antigen. This secondary immune 
response towards the same antigen is the main component of the adaptive immune 
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system. Memory B and T cells are the cells involved in the development of 
immunological memory. Memory B cells are plasma cells that produce antibodies 
while memory T cells are CD4+ and CD8+ T cells that are capable in recognizing 
antigen specifically.  
Allergic rhinitis (AR) is one of the most common allergic diseases, affecting 
about 400 million people worldwide. AR is a major risk factor for poor asthma 
control and markedly impair the quality of life, sleep, social life, school, and work 
performance, leading to a huge socioeconomic burden, with medical costs greater 
than those of diabetes, coronary heart disease and asthma. Improved understanding 
of the underlying immune mechanisms is central to developing precision medicine or 
therapies and to prevent worsening of symptoms.  
Recently, it has been observed that the proportions of CD4+ memory T cell 
populations differ in seasonal AR patients compared to non-allergic controls, in 
parallel to the difference seen in epigenetics in terms of DNA methylation patterns, 
which separated the allergic patients from healthy controls (Nestor et al., 2014). This 
finding represents an important advancement in the understanding of the underlying 
mechanisms, highlighting the potential importance of changes in both epigenomics 
and CD4+ memory T cells in complex immune disease like AR. To date, there are 
only very few studies on CD4+ memory T cells in allergic diseases as described in 
Chapter 2: Literature review (section 2.5). However, these studies collectively 
pointed towards a potential involvement of memory T cell subsets in the 
immunopathogenesis of allergic diseases. 
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These studies focused on seasonal AR patients in which birch and grass 
pollen were the main allergens patients were sensitized to, while in Malaysia we 
have mostly perennial AR patients sensitized to HDMs of Dermatophagoides species 
as the most common allergens. There is a lack of literature on the role of CD4+ 
memory T cells in perennial AR patients which needs to be addressed. In addition, 
no study has investigated the differences in proportion of CD4+ memory T cell 
subsets in different severity of AR, which may shed light on their roles in the 
development of AR from mild to moderate-severe.  
Furthermore, the observations from previous studies were from very small 
sample sizes, so we aimed to look at a bigger sample size to obtain a more reliable 
data on memory T cells in perennial AR. Also, since differences in genetic ancestry 
may influence the observation seen in complex diseases including allergic diseases, 
there is a need to investigate the differences in the proportion of memory T cells in 
our local population, as previous observations were from caucasian populations.  
Targeting the specific CD4+ memory T cell subset in AR patients may 
represent an interesting and novel approach for personalised treatment, e.g. for 
moderate-severe perennial AR patients. Thus, our study is undertaken to investigate 
the proportions of CD4+ memory T cell subsets in perennial AR patients of a 
Malaysian population, in comparison to the healthy controls and in association with 
disease severity. This study is also aimed to provide preliminary data for CD4+ 
memory T cell subsets in AR patients of a Malaysian population. 
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1.2 Problem statement 
This study focuses on the determination of the proportions of CD4+ memory 
T cell subsets in adult AR patients attending Hospital Universiti Sains Malaysia 
(HUSM) in Kelantan. Previously, several studies have been done in AR patients 
attending HUSM (Asha'ari et al., 2010; Ashari, 2009; Wan Majdiah et al., 2011). 
However, these studies focused on the clinical features and the sensitization patterns 
of the AR patients. It is strongly believed that the proportions of CD4+ memory T 
cells and epigenetic changes are the underlying causes of AR.  
Thus, this study was conducted to investigate the proportions of CD4+ 
memory T cells in AR patients compared to healthy controls. First, we identified the 
sensitization patterns of AR patients towards common inhalant and food allergens 
that become the immediate causes of AR. Secondly, the predisposing factors such as 
demographic and environmental factors that may be involved in the development of 
AR are were examined in this study. Finally, the proportions of CD4+ memory T cell 
subsets were determined to identify the changes at cellular level that may become the 
underlying causes of AR.  
 
1.3 Theoretical framework 
This study focuses on determining the immediate and underlying 
determinants that reflect the causes and severity of AR. Firstly, the immediate 
determinant namely sensitization to common allergens i.e. inhalant and food 
allergens were determined to provide reasons for determining the underlying 
determinants. Secondly, predisposing factors such as demographic (age, gender, 
body mass index, smoking status) and environmental factor (home location) were 
examined as these factors may be the underlying determinants that cause AR. 
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Finally, changes at cellular level i.e. proportions of leukocyte subsets and CD4+ 
memory T cell subsets were measured as their changes may be the predominant 
underlying determinants that caused the impairment of the immune system which 
subsequently lead to AR.  
 
 
Figure 1.1: Theoretical framework of determinants of perennial allergic 
rhinitis 
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1.4 Research questions 
1. Which allergens are mild and moderate-severe AR patients predominantly 
sensitized to? 
2. Which predisposing factors cause AR in mild and moderate-severe AR 
patients? 
3. What cellular changes may contribute to the immunopathogenesis of AR in 
mild and moderate-severe AR patients? 
 
1.5 Purpose of study 
This study was conducted in AR patients attending HUSM in Kelantan which 
is located in the North East of Peninsular Malaysia. AR patients from different 
regions of Malaysia may have different clinical features, sensitization patterns, 
predisposing factors and underlying causes i.e. changes at cellular level that 
contribute to the immunopathogenesis of AR. Thus, this study was conducted to 
identify which of these factors may play a role in the immunopathogenesis of AR in 
adult AR patients.  
This study also adds to the literature regarding the proportions of CD4+ 
memory T cell subsets in AR patients from North East of Peninsular Malaysia. We 
hope that the findings of this study can be used to guide other similar perennial AR 
studies in other parts of Malaysia and South East Asia countries. 
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1.6 Rationale of study population 
The reason for choosing AR patients attending HUSM as the study population 
was mainly because the AR patients were diagnosed by ear, nose and throat (ENT) 
specialists from Otorhinolaryngology-Head and Neck Surgery (ORL-HNS) clinic in 
HUSM. They were given proper diagnosis of AR as nasal endoscopic examination 
was done to AR patients and this examination may not be done in other clinics in 
Kelantan. This examination confirms the inflammation of the membranes lining the 
nose suffered by AR patients. Furthermore, HUSM is a tertiary referral hospital in 
Kelantan where AR patients can be easily recruited with the help of ENT specialists 
and nurses from ORL-HNS clinic. 
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1.7 Objectives 
1.7.1 General objective 
To determine the mean percentages and mean absolute counts of CD4+ T cell 
subsets (naïve, central memory, effector memory and terminally differentiated 
effector memory) in AR patients attending Hospital Universiti Sains Malaysia and 
non-allergic controls. 
 
1.7.2 Specific objectives 
1. To determine the demographic and clinical characteristics of AR patients and 
non-allergic controls. 
2. To determine the sensitization to common allergens among physician-
diagnosed AR patients. 
3. To compare AR symptom severity scores and quality of life scores between 
mild and moderate-severe AR patients. 
4. To compare mean absolute counts of leukocyte subsets between: 
a. AR patients and non-allergic controls. 
b. Mild and moderate-severe AR patients. 
5. To compare mean percentages and absolute counts of CD4+ T cell subsets 
(naïve, central memory, effector memory and terminally differentiated 
effector memory) between: 
a. AR patients and non-allergic controls. 
b. Mild and moderate-severe AR patients. 
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1.8 Hypothesis 
1. There is a difference in the demographic and clinical characteristics between 
AR patients and non-allergic controls. 
2. There is a difference in sensitization to common allergens between mild and 
moderate-severe AR patients in physician-diagnosed AR patients. 
3. There is a difference in AR symptom severity scores and quality of life scores 
between mild and moderate-severe AR patients. 
4. There is a difference in mean absolute counts of leukocyte subsets between: 
a. AR patients and non-allergic controls. 
b. Mild and moderate-severe AR patients. 
5. There is a difference in mean percentages and absolute counts of CD4+ T cell 
subsets (naïve, central memory, effector memory and terminally 
differentiated effector memory) between: 
a. AR patients and non-allergic controls. 
b. Mild and moderate-severe AR patients. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
Previous literature is reviewed in this chapter to provide detailed explanation 
about the important topics addressed in this study. This chapter consists of six major 
topics that describe the overall study. Firstly, allergy and allergic rhinitis (AR) are 
explained in detail. Secondly, the immunopathogenesis and immune cells that are 
involved in allergic inflammation of AR are elaborated. Finally, the role of CD4+ 
memory T cells in allergy as well as CD4+ memory T cell subsets and their markers 
investigated in this study are clearly explained. 
 
2.1 Allergy 
Allergy is an antibody and cell mediated hypersensitivity reaction in response 
to a normally harmless substance known as allergen (Johansson et al., 2001). 
Allergic immune response involves the production of specific immunoglobulin E 
(IgE) antibody by plasma cells towards the allergen (Sircar et al., 2014) and the 
binding of these specific antibodies to FcεRI on mast cells, basophils and 
eosinophils, leading to the release of mediators like histamines. The involvement of 
CD4+ T lymphocytes is central in the allergic response as they secrete TH2 cytokines 
in response to activation by allergens, with the long-lived human memory TH2 cells 
playing an important role as they are allergen-specific (Woodfolk, 2007). The 
development of allergic diseases is frequently associated with atopy, which refers to 
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the personal or familial tendency in producing IgE antibodies in response to 
sensitized allergens (Tanno et al., 2016). 
Allergy can be categorized into respiratory, skin and gastrointestinal allergies 
where the symptoms commonly manifest in allergic individuals. Allergic rhinitis 
(AR) and allergic asthma are the respiratory allergies manifested in the upper 
respiratory tract and lower respiratory tract of the respiratory system respectively 
(Brooks et al., 2017). The most common skin allergies are atopic dermatitis (AD) 
and urticaria (Schlapbach and Simon, 2014) while food allergies such as cow’s milk 
allergy are usually manifested as gastrointestinal allergy (Wuthrich, 2014), although 
the symptoms can be observed in skin and respiratory system as well. These allergic 
diseases commonly co-exist, typically following the atopic march (Figure 2.1), where 
the development of AD in infancy precedes the development of AR and asthma at 
later stages in life (Bantz et al., 2014; Spergel, 2010). Allergic inflammation can be 
divided into early-phase reaction where the symptoms start to appear within minutes 
of allergen exposure, and late-phase reaction where the symptoms develop in a few 
hours after allergen exposure (Galli et al., 2008).  
 
 
Figure 2.1: The incidence of atopic march. Adapted from (Spergel, 2010). 
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2.2 Allergic rhinitis (AR) 
AR is clinically defined as IgE-mediated inflammation of membranes lining 
the nose after allergen exposure associated with nasal symptoms including 
rhinorrhea, sneezing, nasal obstruction and nasal itchiness (Bousquet et al., 2008). 
The symptoms of AR usually impact the quality of life by causing sleep 
disturbances, reduced work or school performance and abnormal daily activities. In 
addition, comorbidities such as asthma, sinusitis, AD and otitis media are commonly 
associated with AR (Bousquet et al., 2008). Although AR is not a very serious 
medical condition that causes severe morbidity and mortality but it has become a 
frequent reason for the sufferers to seek treatment from the physician (Brozek et al., 
2017). This leads to a huge negative impact to the economy, with the total costs 
related to AR estimated to be up to US$20.9 billion in the United States (Pawankar, 
2014). In societies with emerging economies like the Asia Pacific region, indirect 
losses e.g. due to loss of productivity caused by AR further impact the financial 
outcome, resulting in annual per-patient costs that ranged from US$ 184 to US$ 
1,189. Therefore, the cost of allergic rhinitis should not be underestimated as it can 
be enormous (Kushnir et al., 2015).  
 
2.2.1 Prevalence of AR 
Currently AR is affecting 10% to 40% of the population worldwide (Brozek 
et al., 2017). It has been estimated that 40% of adults and 25% of children worldwide 
suffer from AR. This disease is also very common in many countries in South East 
Asia region (Katelaris et al., 2012). The prevalence of AR in different regions of the 
world is shown in Figure 2.2 and its prevalence in South East Asia countries is 
described in Table 2.1. 
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Figure 2.2: Prevalence of allergic rhinitis in different regions of the world. Adapted 
from (Katelaris et al., 2012). 
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Table 2.1: Prevalence of allergic rhinitis in South East Asia Countries. Adapted from 
(Katelaris et al., 2012). 
Country Population 
characteristics 
Study 
location 
type 
Study design / 
method for 
assessing 
prevalence 
Prevalence 
of AR (%) 
(lifetime, 
unless 
stated 
otherwise) 
Reference 
Malaysia 409 children 
  aged 12 – 20   
  years 
  (Chinese  
  ethnic only) 
Kota 
Kinabalu 
(urban) 
Questionnaire 
and skin prick 
tests  
11.2% AR (Leung 
and Ho, 
1994) 
Singapore 9636 children 
  aged 6 – 15 
  years 
 
2868 adults 
  aged 20 – 74  
  years 
Singapore 
(urban) 
 
 
Singapore 
(urban) 
 
ISAAC study 
questionnaires 
 
 
Standardized 
questionnaire 
25.5 – 
42.1% AR 
within past 
12 months 
5.5% AR 
(Wang et 
al., 2004) 
 
 
(Ng and 
Tan, 
1994) 
Thailand 7341 children 
  aged 6 – 14 
  years    
 
Bangkok 
and its 
vicinity 
ISAAC study 
questionnaires 
 
17.9 – 
44.2% AR 
(Bunnag 
et al., 
2009) 
Vietnam 7008 adults 
  aged 21 – 70  
  years  
Hoankiem 
(urban) 
and  
Bavi  
(rural) 
in Hanoi 
FinEsS 
questionnaire 
modified from 
Swedish 
OLIN 
study 
questionnaire 
50.2% AR 
 
(Lam et 
al., 2011) 
Abbreviations: AR, allergic rhinitis; FinEsS, Finland, Estonia and Sweden; ISAAC, 
International Study of Asthma and Allergies in Childhood; OLIN, Obstructive Lung 
Disease in Northern Sweden.  
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2.2.2 Aetiology of AR 
AR is usually caused by aeroallergens inhaled by allergic individuals. Based 
on the timing of exposure, AR can be classified into perennial AR which can occur at 
any time throughout the year or seasonal AR which usually occur in certain seasons 
in a year based on the presence of the aeroallergens exposed yearly (May and Dolen, 
2017). The most common aeroallergens associated with perennial AR are house dust 
mites (HDMs) and animal dander. The global major HDMs species are 
Dermatophagoides pteronyssinus (Der p), Dermatophagoides farinae (Der f), 
Euroglyphus maynei and Blomia tropicalis (Calderon et al., 2015). Cat (Felix 
domesticus) and dog (Canis familiaris) danders are the common aeroallergens from 
pets that cause allergic reactions in perennial AR (Passali et al., 2018). Meanwhile, 
pollens from birch (Betulaceae family) and grass (Poaceae family) are the main 
aeroallergens causing seasonal AR (Asam et al., 2015; Garcia-Mozo, 2017).  
Although AR is frequently associated with allergic sensitization to 
aeroallergens, sensitization to foods may also induce AR (Cingi et al., 2010). The 
true prevalence of food-induced AR is difficult to identify as it frequently occurs in 
association with other food allergy symptoms such as asthma, eczema, oral allergic 
manifestations, urticaria and gastrointestinal symptoms. Cross reactivity between a 
pollen allergen and a homologous protein allergen in raw fruits or vegetables (e.g. 
birch pollen protein Bet v 1 and the homologous Mal d 1 protein in apple or Dau d 1 
in carrot) may result in allergic sensitization in AR patients (Breiteneder and Mills, 
2005; Malik et al., 2007). 
HDMs are the most common allergens causing allergic sensitization among 
AR patients in Malaysia (Asha'ari et al., 2010; Ashari, 2009; Gendeh et al., 2004). 
They are commonly found as indoor allergens in human habitats (Calderon et al., 
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2015). The critical factor for the HDMs prevalence both inside and outside the home 
is humidity as their concentrations were found to be higher in damp homes, and 
Malaysia has continuous warm and humid environment throughout the year which 
enable the growth and proliferation of HDMs. HDMs also are more frequently found 
in beds than carpets at home because the relative humidity start to increase quickly 
after a bed is occupied (Calderon et al., 2015). 
Studies found that AR patients in Malaysia were mostly sensitized to HDMs 
of Dermatophagoides species such as Der f and Der p (Leung and Ho, 1994; Liam et 
al., 2002; Wan Majdiah et al., 2011). Furthermore, it has been observed that cat 
dander was another major aeroallergen that caused AR among adults and children in 
Malaysia (Asha'ari et al., 2010; Gendeh et al., 2004). Several studies in Malaysia 
found that food allergens also induced allergic sensitization in AR patients, 
especially shellfish such as shrimp and crab (Gendeh et al., 2004; Gendeh et al., 
2000; Wan Majdiah et al., 2016).  
 
2.2.3 Predisposing factors of AR 
 AR is a disease that is commonly found in adults and children (Brozek et al., 
2017). It can be found across all age groups from childhood to adolescence to late 
adulthood (Blomme et al., 2013; Eriksson et al., 2011). The prevalence of AR has 
been found to be significantly decreased in 65 – 84 years age class compared to 20 – 
44 years age class in both men and women (Cazzoletti et al., 2015). Other studies 
also found that the prevalence of AR peaks at the age of 16 – 24 years old and it 
decreases in the following years up to the age of 65 – 70 years old (Droste et al., 
1996; Olivieri et al., 2002). The decrease of AR prevalence in late adulthood could 
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be due to the decrease in the specific IgE level that occurs with aging in atopic 
individuals (Slavin, 2006). 
AR is commonly present in both male and female gender. A systemic review 
and meta-analysis on AR found that the prevalence of AR in adults was not sex-
specifc (Pinart et al., 2017). However, a consistent male predominance of AR was 
found in children aged of 3 – 13 years old (Keil et al., 2010). Findings from the Isle 
of Wight Birth Cohort showed that AR was predominantly found in male at the age 
of 1 – 2 years old but significant difference in gender was not found in the 
prevalence of AR in the following first 18 years of life (Kurukulaaratchy et al., 
2011). Cross-sectional surveys in the north-east of England found that AR 
prevalence are higher in pre-pubertal males aged 6 – 7 years old and adolescent girls 
age 13 – 14 years old (Shamssain and Shamsian, 1999; Shamssain and Shamsian, 
2001). The higher prevalence of AR in adolescent girls could be due to the role of 
estrogens as female hormones have been found to play a role in allergic diseases 
(Bonds and Midoro-Horiuti, 2013). These findings indicate that gender may 
influence the occurance of AR at different age groups. 
It is known that the increasing prevalence of asthma and allergy in recent 
years has been associated with the increase prevalence of obesity (Noal et al., 2011). 
Obesity has been associated with asthma in several populations in childhood and 
adolescence (Baruwa and Sarmah, 2013). A cross-sectional study in 5,218 adults in 
United States showed that being overweight or obese was associated with increased 
risk of having AR (Gogna et al., 2015). However, similar association was not found 
in children in the study. Another study in 3,327 allergic children in Wuhan City of 
China observed that obesity increased the prevalence of AR and AD in children (Lei 
et al., 2016). These findings indicate obesity increase the risk of AR in both adults 
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and children. Studies have demonstrated that leptin which is adipokines was 
associated with allergen exposure and severity of AR in AR patients (Ciprandi et al., 
2009; Hsueh et al., 2010). Thus, adipokines which is fat related hormones could be 
involved in the association of obese and AR. 
A recent systematic review and meta-analysis on association of smoking and 
allergic diseases has observed very modest associations between smoking and some 
allergic diseases in adults (Saulyte et al., 2014). A study on the effect of smoking on 
symptoms of AR found that smoking was not associated with the severity of nasal 
symptoms in AR patients (Bousquet et al., 2009). Recently, smoking has been 
observed to be associated with the significant increase in the occurance of chronic 
rhinitis but not AR in self-reported or physician diagnosed AR patients (Hisinger-
Molkanen et al., 2018). These findings suggest that the association between nasal 
symptoms and tobacco smoke exposure may be independent of allergy. 
Prevalence of AR is higher in the urban areas compared to rural areas based 
on several studies (Nicolaou et al., 2005). The prevalence of chronic nasal symptoms 
in self-reported AR patients in West Sweden has been found to be associated with 
the increasing degree of urbanization (Eriksson et al., 2011). Urban area is frequently 
associated with heavy traffic. Several studies have described the relation between 
traffic density and AR (Montnemery et al., 2003; Weiland et al., 1994). It was found 
that traffic density was positively correlated with the prevalence of wheezing and AR 
in children (Weiland et al., 1994). Other study suggested that living on busy roads is 
associated with higher risk of sensitization to pollen allergens in allergic children 
(Kramer et al., 2000). Collectively, these findings suggest that urbanization and 
heavy traffic density are associated with the increased prevalence of AR in urban 
areas. 
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2.2.4 Diagnosis of AR  
AR is diagnosed mainly by the history of nasal symptoms, nasal endoscopic 
examination by the physician and history of allergy (Bousquet et al., 2008). Patients 
are suggested to have AR if they have two or more of the symptoms assessed such as 
watery anterior rhinorrhea, sneezing especially paroxysmal, nasal obstruction, nasal 
pruritus and conjunctivitis for more than one hour on most days (Bousquet et al., 
2008). Although AR patients frequently have non-nasal symptoms such as eye 
symptoms, throat symptoms, chronic cough, ear symptoms, headache and mental 
function (cognitive) impairment (Spector et al., 2003) but the assessment of these 
non-nasal symptoms were not included in diagnosis of AR. The assessment of these 
non-nasal symptoms can be used to further support the severity of AR (Wallace et 
al., 2008).  
The parameters examined for nasal endoscopic examination are presence of 
nasal secretions, erythematous or pale of nasal mucosa, nasal septum deviation, 
inferior turbinate hypertrophy, narrow internal nasal valve and nasal polyps (Ziade et 
al., 2016). These parameters are examined to exclude other sinonasal diseases (Y and 
Gupta, 2016). Nasal features including transverse crease of the nose (Ramot et al., 
2010) and dark circle under the eyes, also known as allergic shiners (Chen et al., 
2009), can further support the diagnosis of AR.   
There are several diagnostic tests that can be done to determine the allergens 
causing allergic sensitization in AR patients. Phadiatop enzyme-linked 
immunosorbent assay (ELISA) test is one of the assays used to determine the degree 
of sensitization to aeroallergens based on the presence of specific IgE to a mixture of 
common aeroallergens (Vidal et al., 2005). However, this assay is unable to 
individually identify the specific aeroallergens that cause sensitization in AR 
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patients. Skin prick test (SPT) (Nevis et al., 2016) and allergen specific IgE 
immunoassay using blood samples (Posa et al., 2017) are respectively, the clinical 
and laboratory gold standard allergic tests used to confirm the underlying allergic 
sensitization that causes AR. Both tests can be used to determine the aeroallergens 
and food allergens AR patients are sensitized to. Studies have shown that there were 
good correlations between in vivo SPT and in vitro specific IgE immunoassay (Cho 
et al., 2014a; Wongpiyabovorn et al., 2017). Therefore, either SPT or specific IgE 
immunoassay can be used as a diagnostic test to determine the culprit allergens. 
However, both tests have their own advantages and disadvantages. SPT is commonly 
used by allergist as primary tool to detect the culprit allergens because of its high 
sensitivity, rapidity and inexpensiveness (Cox et al., 2008; Wongpiyabovorn et al., 
2017). It is convenient to perform this test because no machine is required. 
Meanwhile, specific IgE immunoassay usually becomes the alternative tool in 
detection of culprit allergens because it is machine requirement test. It is expensive 
and lack of rapidity in giving results compared to SPT. However, the results obtained 
through this test are lessly affected by skin condition and medication. Most 
importantly, this in vitro immunoassay has no risk of severe allergic reaction that 
will occur to the allergic patients in comparison to the in vivo SPT (Wongpiyabovorn 
et al., 2017). 
Another diagnostic test that can determine the allergens AR patients are 
sensitized to is intradermal skin test. A study showed that AR patients with negative 
SPT results to HDMs appeared to be positive to HDMs after intradermal skin test 
was done (Erel et al., 2017). Therefore, intradermal skin test can be considered as an 
alternative in vivo diagnostic test to determine allergens causing sensitization in AR 
patients if in vitro diagnostic tests are not available. Multiple allergen components of 
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specific IgE antibodies can be detected simultaneously by using immuno-solid phase 
allergen chip (ISAC) (Griffiths et al., 2017; van Hage et al., 2017). This multiplex in 
vitro diagnostic tool is able to provide the allergen specific IgE antibody profile of 
AR patients. A study showed that ISAC can be used as a diagnostic tool to determine 
the allergen components that have cross-reactivity with HDMs in polysensitized AR 
patients (Mohamad Yadzir et al., 2014). The measurement of the eosinophil 
(Makihara et al., 2014; Peric et al., 2017), tryptase (Di Cara et al., 2017; Kim et al., 
2016) and eosinophilic cationic protein (Di Cara et al., 2017; Kim et al., 2016) are 
other diagnostic parameters that can further support the diagnosis of AR as these 
parameters are commonly associated with the allergic inflammation in AR patients. 
The severity of AR is classified into mild and moderate-severe based on the 
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines (Bousquet et al., 
2008). Sleep abnormality, impairment of daily activities, impairment of work or 
school performance and troublesome symptoms are the four items measured to 
determine the severity of AR. An AR patient is diagnosed as having a mild AR if 
he/she has none of the four items, while the diagnosis of moderate-severe AR is 
made if an AR patient has at least one of the four items measured. The ARIA 
guidelines also classified the symptoms of AR into intermittent and persistent 
symptoms based on the duration of the symptoms presented in AR patients. 
Intermittent symptoms are associated with the presence of symptoms for less than 
four days per week or less than four consecutive weeks; while persistent symptoms 
are associated with the presence of symptoms for more than four days per week and 
more than four consecutive weeks. The summary of AR severity and classification of 
symptoms is as shown in Figure 2.3. 
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Figure 2.3: Summary of allergic rhinitis severity and classification of symptoms 
based on Allergic Rhinitis and its Impact on Asthma guidelines (Bousquet et al., 
2008). 
 
2.2.5 Treatment of AR 
AR can be managed through allergen avoidance (Platts-Mills, 2004), 
pharmacotherapy (May and Dolen, 2017) and immunotherapy (Rajakulasingam et 
al., 2018). Currently, pharmacotherapy is considered to be the cornerstone in 
managing most cases of AR (Ridolo et al., 2014) because the standard allergen 
avoidance alone does not give positive results in the management of AR (Solelhac 
and Charpin, 2014). Allergen avoidance by using mite-proof bedding covers have 
been shown to reduce the HDMs exposure but no significant improvement in the 
clinical symptoms of AR patients were observed (Terreehorst et al., 2003). This 
observation suggested that the measured HDMs on the mattress surface did not 
reflect the allergens inhaled by AR patients (Tovey et al., 2003). Several studies 
showed that the major cat allergen, Fel d 1, was found in the floor dust from homes 
(Custis et al., 2003; Fahlbusch et al., 2002) and hospital (Custovic et al., 1998) even 
with the absence of cat in both places. These observations suggest that not having a 
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pet was not effective in managing AR. Therefore, standard allergen avoidance alone 
was no longer considered to be the cornerstone in the management of most cases of 
AR (Solelhac and Charpin, 2014). 
The common pharmacotherapy for AR patients is intranasal corticosteroids 
(Trangsrud et al., 2002) and antihistamines (Hernandez-Trujillo, 2009). Although 
AR is a systemic disease (Blanca et al., 2015; Campo et al., 2013), systemic steroids 
are not recommended in treating AR due to increased risk of diabetes and 
osteoporosis (Aasbjerg et al., 2013). Intranasal corticosteroids that are commercially 
available to treat AR in adults and children are beclomethasone dipropionate, 
budesonide, flunisolide, fluticasone propionate, mometasone furoate and 
triamcinolone acetonide (Braido et al., 2008). The intranasal corticosteroids have 
been proven to improve the symptoms of AR by reducing the nasal mucosa 
hyperreactivity through the anti-inflammatory action exerted by these medications 
(Bousquet et al., 2008). Antihistamines has been classified into first-generation and 
second-generation drugs (Hoyte and Katial, 2011) used to treat AR. The usage of 
first-generation antihistamines should be avoided as these drugs penetrate into the 
brain and caused sedation, drowsiness and fatigue which may impair the ability to 
work and drive (Church and Church, 2013). Currently, second-generation 
antihistamines such as loratadine, levocetirizine, fexofenadine, bilastine, rupatadine 
and desloratadine are widely used in treating AR (Recto et al., 2017). These drugs 
have been shown to rapidly reduce the nasal and ocular symptoms of AR with the 
improvement in the quality of life in most AR patients (Demoly et al., 2014).  
Allergen-specific immunotherapy is the only current treatment that may 
potentially decrease or resolve the underlying allergic inflammation in AR 
(Mortuaire et al., 2017). Currently, subcutaneous immunotherapy (SCIT) and 
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sublingual immunotherapy (SLIT) have been used to treat AR patients (Durham and 
Penagos, 2016). AR patients with uncontrolled symptoms although on 
pharmacotherapy treatment should consider allergen-specific immunotherapy as an 
alternative treatment to manage the disease (Bousquet et al., 2008). SCIT has been 
shown to be highly effective to treat seasonal AR as significant reduction in the 
symptom scores have been observed in the seasonal AR patients (Calderon et al., 
2007). SCIT has also been observed to be effective and safe to use in perennial AR 
adults and children with HDM sensitization (Eifan et al., 2013). Similar to SCIT, 
SLIT is safe and effective to treat seasonal AR (Canonica et al., 2014) but its 
efficacy in treating HDM allergy in perennial AR patients especially in AR children 
is less convincing (Calderon et al., 2013). Currently, there is no specific lower age 
limit to start allergen-specific immunotherapy (Canonica et al., 2014). However, 
SLIT is a favorable and attractive option of allergen-specific immunotherapy in 
young children and their caregivers compared to SCIT. This is because SLIT can be 
administered to the young children without the usage of needles and frequent trips to 
the medical clinic. Furthermore, SCIT is not frequently prescribed to the young 
children mainly because of concern that they may have difficulty in communicating 
the symptoms of systemic reactions during the immunotherapy program (Canonica et 
al., 2014). The third update of Allergen Immunotherapy: A Practice Parameter (Cox 
et al., 2011) states that immunotherapy can be given to the young children aged less 
than five years old if recommended. The recommendations must be based on the 
severity of the disease, risk/benefit ratios, and the physician’s ability to correlate the 
clinical presentation with suitable allergy testing. This practice parameter of allergen 
immunotherapy was updated after studies that evaluated the safety of SCIT in 
children aged less than five years old reported a similar incidence and severity of 
